View Part 1 on active immunotherapies
Monoclonal antibodies targeting beta-amyloid have produced a series of disappointments. Two phase III trials of bapineuzumab showed no significant effect on ADAS-cog or Disability Assessment for Dementia scores in patients with mild to moderate AD either with or without the APOE4 allele (Salloway et al. N Engl J Med 2014;370:322-333). A similar lack of efficacy was seen in the two phase III EXPEDITION studies of solanezumab (Doody et al. N Engl J Med 2014;370:311-321). Solanezumab is now being studied in patients with early-stage AD.